Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.57 |
| ▸ | CACNA1I | Q9P0X4 | 14/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 14/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 13/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843773 | 0.84 | CYP11B2 (0.40) | CYP11B2 | |
| SCHEMBL843156 | 0.83 | CYP11B2 (0.44) | CYP11B2 | |
| SCHEMBL843460 | 0.82 | CYP11B2 (0.41) | CYP11B2CACNA1ICACNA1GCACNA1HCYP11B1 | |
| SCHEMBL2816867 | 0.75 | CYP11B2 (0.47) | CYP11B2CYP3A4 | |
| SCHEMBL10644234 | 0.73 | CYP11B2 (0.45) | CYP11B2CYP3A4 | |
| SCHEMBL842755 | 0.72 | CYP11B2 (0.52) | CYP11B2 | |
| SCHEMBL2819443 | 0.69 | CYP11B2 (0.46) | CYP11B2POLBCYP3A4 | |
| SCHEMBL2819445 | 0.69 | CYP11B2 (0.46) | CYP11B2POLBCYP3A4 | |
| SCHEMBL2819441 | 0.69 | CYP11B2 (0.46) | CYP11B2POLBCYP3A4 | |
| SCHEMBL2820634 | 0.68 | CYP11B2 (0.41) | CYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | CYP11B2 3/4885CACNA1I 2647/4885CACNA1G 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.